News Image

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Provided By GlobeNewswire

Last update: Aug 13, 2024

Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies

Read more at globenewswire.com

DARE BIOSCIENCE INC

NASDAQ:DARE (8/22/2025, 8:01:42 PM)

After market: 2.2 +0.08 (+3.77%)

2.12

+0.02 (+0.95%)



Find more stocks in the Stock Screener

Follow ChartMill for more